Physician profile
Tom Macek
NPI 1528129988
$12,396.95
in general payments reported to CMS, 2019-2025
39 companies · $779 in 2025
The $779 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $2,106 · 2021: $2,176 · 2022: $2,323 · 2023: $1,671 · 2024: $1,395 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,074.56 | 2019-2023 | Proclaim |
| Abbvie INC. | $1,480.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,357.47 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $990.53 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $976.75 | 2019-2025 | Xtampza |
| Zyla Life Sciences, INC. | $567.86 | 2019-2020 | |
| Pfizer INC. | $385.87 | 2019-2025 | |
| Nevro Corp. | $345.90 | 2019-2024 | Senza |
| Horizon Therapeutics Plc | $234.65 | 2019-2022 | |
| Redhill Biopharma INC. | $215.97 | 2020-2022 | |
| Orexo US, INC. | $192.33 | 2022-2024 | Zubsolv |
| Boston Scientific Corporation | $188.45 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $155.99 | 2019-2022 | |
| Ibsa Pharma INC. | $149.85 | 2023-2025 | Tirosint, Licart, Tirosint |
| Biodelivery Sciences International, INC. | $127.74 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Macek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.